Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carfilzomib + Lenalidomide + Dexamethasone + Elotuzumab
- Development stage
- Unknown
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
CRD-002 is a code name for an experimental, not FDA-approved, quad-drug combination therapy comprising elotuzumab, carfilzomib, lenalidomide, and dexamethasone. This regimen is being investigated for the treatment of relapsed/refractory multiple myeloma. Elotuzumab is a monoclonal antibody that targets SLAMF7, carfilzomib is a proteasome inhibitor, lenalidomide is an immunomodulatory drug, and dexamethasone is a corticosteroid. The combination aims to evaluate the efficacy in achieving a very good partial response or better in patients.
02
Targets
CRBN (Cereblon)GR (Glucocorticoid receptor)SLAMF7 (Signaling lymphocytic activation molecule family member 7)26S proteasome
Beyond the preview
Go deeper on Carfilzomib + Lenalidomide + Dexamethasone + Elotuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Carfilzomib + Lenalidomide + Dexamethasone + Elotuzumab.